1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety, and immunogeniity of heptavalent pneumococcal cojugate vaccine in children. Pediatr Ifect Dis J2000;19:187-195.
2.
2. American Academy of Pediatrics, Committee on Infectious Diseases. Policy Statement: Recommendations for the prevention of pneumococcal infections, including the use of pnemococcal conjugate vaccine (Prvnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
3.
3. Dagan R, Givon N, Yaguspsky P, et al. Effect of a 9-valent pneumococcal vacine conjugated to CRM197 on nsopharyngeal carriage of vaccine type and nonvaccine type S. pneumoniae strains among day care attendees. 38th Interscience Conference on Atimicrobial Agents and Chemotheapy, September 24-27, 1998, San Diego, CA.
4.
4. Eskola J, Kilpi T, Palmu A, et al. Effcacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
5.
5. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among ifants with sickle cell disease. Pediatrics. 2000;106:965-972.
6.
6. Wuorimaa T, Dagan R, Eskola J, et al. Tolerability and immunogenicity of an eleven-valent pneumococcal cojugate vaccine in healthy toddlers. Pdiatr Infect Dis J. 2001;20:272-277.
7.
7. Adamou JE, Heinrichs JH, Erwin AL, et al. Identification and characteriztion of a novel family of pneumococal proteins that are protective against sepsis. Infect Immun. 2001;69:949-958.
8.
8. Overweg K, Kerr A, Sluijter M, etal. The putative proteinase maturation protein A of Streptococcus pneumoniae is a coserved surface protein with potential to elicit protective immune responses. Ifect Immun. 2000;68:4180-4188.
